Matthew J. Matasar, MD, on the Clinical Implications of the Phase 3 CHRONOS-3 Study

Video

The lymphoma expert discussed how adding copanlisib to rituximab improved progression-free survival, while demonstrating a manageable safety profile in patients with relapsed indolent non-Hodgkin lymphoma.

Adding copanlisib (Aliqopa) to rituximab (Rituxan) reduced the risk of disease progression or death, compared with rituximab plus placebo, in patients with relapsed indolent non-Hodgkin lymphoma, according to primary results from the phase 3 CHRONOS-3 study (NCT02367040).

At the virtual American Association for Cancer Research Annual Meeting, Matthew J. Matasar, MD, presented results from the trial, showing that the median progression-free survival with copanlisib/rituximab was 21.5 months (95% CI, 17.8-33.0) compared with 13.8 months (95% CI, 10.2-17.5) with rituximab/placebo (HR, 0.520; 95% CI, 0.393-0.688; P <.0001). Moreover, the combination demonstrated a manageable safety profile that was consistent with prior reports of copanlisib and rituximab as single agents.

“Our hope is that with copanlisib…[we] might be able to overcome those challenges and prove to be a safe and effective medicine when combined with rituxumab.,” Matasar, associate member of Lymphoma Service, Department of Medicine, at Memorial Sloan Kettering Cancer Center, said in an interview with CancerNetwork®.

He further discussed the trial results and the clinical implications they may have for patients with relapsed indolent non-Hodgkin lymphoma.

Transcription:

The takeaway here is that the combination of copanlisib with rituximab was shown to be safe and effective. Safe, meaning we didn’t find any unexpected toxicities or signal that wasn’t expected given what we know about the agents alone, and effective, meaning that it significantly improved progression-free survival. Patients on average were able to stay in remission longer with the combination than with rituximab alone.

I think that these data really do support the use of the combination of rituximab with copanlisib as a standard treatment for patients with indolent relapsed B-cell lymphomas whose disease has been sensitive to rituximab in the past. I really think that this establishes the treatment as safe and effective and a very reasonable consideration for such patients.

We’re continuing to work on how best to leverage copanlisib in clinical practice. We’ve recently completed a sister study called CHRONOS-4, which is again a randomized clinical trial comparing rituximab in combination with bendamustine or rituximab plus CHOP [cyclophosphamide, doxorubicin, vincristine and prednisone], with or without copanlisib, to see whether copanlisib can be safely combined with chemoimmunotherapy to improve outcomes for patients with indolent lymphomas.

Reference

Matasar MJ, Capra M, Ozcan M, et al. CHRONOS-3: randomized phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL). Presented at: 2021 AACR Annual Meeting 2021; April 10-15, 2021; virtual. Abstract CT001.

Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
Related Content